UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
______________
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of December 2012
Commission File Number: 001-34541
CHINA CORD BLOOD CORPORATION
(Translation of registrant’s name into English)
48th Floor, Bank of China Tower
1 Garden Road
Central
Hong Kong S.A.R.
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-_______________.
This report and each of the exhibits to this report are hereby incorporated by reference into the registration statements on Form F-3 (No. 333-168873 and No. 333-183143) of the Company.
Other Events
On December 20, 2012, China Cord Blood Corporation (the “Company”) issued a press release announcing the results of its 2012 Annual General Meeting, which was held on December 19, 2012, in Hong Kong. At the 2012 Annual General Meeting, shareholders: (1) elected Mr. Yuen Kam, Mr. Julian J. Wolhardt and Ms. Jennifer J. Weng to serve on the Board of Directors, with Mr. Yuen Kam as Chairman of the Board, until the 2015 annual general meeting of the Company or until their respective successors are duly appointed and qualified; (2) ratified the appointment of KPMG as independent auditor of the Company for the financial year ending March 31, 2013, and authorized any duly formed committee of the Board of Directors to set the remuneration of the auditors; and (3) passed a special resolution to amend the articles of association of the Company to change the threshold required to approve any future special resolutions from 75% of the votes cast to 66 2/3%, and authorized the directors to make all necessary filings and undertake all such matters, including without limitation, all filings with the Registrar of Companies in the Cayman Islands in respect of the amendments to articles of association.
A copy of the press release is attached hereto as exhibit 99.1.
Exhibits
| Exhibit No. | Description | |
| 99.1 | Press Release, dated December 20, 2012, regarding results of annual general meeting |
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CHINA CORD BLOOD CORPORATION | ||
| By: | /s/ Albert Chen | |
| Name: Albert
Chen Title: Chief Financial Officer | ||
Dated: December 20, 2012
Exhibit 99.1
China Cord Blood Corporation Announces
Results of 2012 Annual General Meeting
HONG KONG, China, December 20, 2012 - China Cord Blood Corporation (NYSE: CO) (“CCBC” or the “Company”), the first and largest cord blood banking operator in China, today announced the results of its 2012 Annual General Meeting, which was held on December 19, 2012, in Hong Kong.
At the Annual General Meeting, shareholders
| · | Ratified the appointment of KPMG as the independent auditor of the Company for the financial year ending March 31, 2013, and authorized any duly formed committee of the directors to fix the remuneration of the auditors; and |
| · | Elected Mr. Yuen Kam, Mr. Julian J. Wolhardt and Ms. Jennifer J. Weng to serve on the Board of Directors until the 2015 Annual General Meeting of the Company or until their respective successors are duly appointed and qualified, and Mr. Yuen Kam will be the chairman of the board of directors; and |
| · | Passed a special resolution to amend the articles of association of the Company to change the threshold required to approve future special resolutions from 75% of the votes cast to 66 2/3%, and authorized the directors to make all necessary filings in respect of the amendments to the article of association. |
About China Cord Blood Corporation
China Cord Blood Corporation is the first and largest cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses. Under current PRC government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and only seven licenses have been authorized as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services. For more information, please visit our website at http://www.chinacordbloodcorp.com.
Safe Harbor Statement
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, performance and results of operations, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in statements filed from time to time with the U.S. Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
For more information, please contact:
China Cord Blood Corporation
Investor Relations Department
Tel: (+852) 3605-8180
Email: [email protected]
ICR, Inc.
Mr. Rob Koepp
Tel: (+86) 10-6583-7516 (China) or (646) 405-5185 (U.S.)
Email: [email protected]